CVE:EPI ESSA Pharma (EPI) Stock Price, News & Analysis C$8.20 +0.55 (+7.19%) As of 10/30/2020 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ESSA Pharma Stock (CVE:EPI) Get ESSA Pharma alerts:Sign Up Key Stats Today's RangeC$7.33▼C$8.2050-Day RangeC$8.20▼C$8.2052-Week RangeC$4.00▼C$11.34Volume1,430 shsAverage Volume4,834 shsMarket CapitalizationC$237.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada. Read More Receive EPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ESSA Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPI Stock News HeadlinesESSA Pharma Completes Acquisition by XenoTherapeuticsOctober 9, 2025 | tipranks.comESSA Pharma Securityholders Approve Acquisition by XenoTherapeuticsOctober 6, 2025 | tipranks.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.July 2 at 1:00 AM | Stansberry Research (Ad)ESSA Pharma Faces Class Action Lawsuit in CaliforniaOctober 3, 2025 | tipranks.comESSA Pharma Receives Court Approval for AcquisitionSeptember 30, 2025 | tipranks.comESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder TermsSeptember 24, 2025 | tipranks.comESSA Pharma Reschedules Special Meeting for AcquisitionSeptember 10, 2025 | tipranks.comEssa Pharma (EPIX) Nosedives 66% Ahead of Business ShutdownAugust 27, 2025 | insidermonkey.comSee More Headlines EPI Stock Analysis - Frequently Asked Questions How have EPI shares performed this year? ESSA Pharma's stock was trading at C$8.20 at the start of the year. Since then, EPI stock has increased by 0.0% and is now trading at C$8.20. How do I buy shares of ESSA Pharma? Shares of EPI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ESSA Pharma investors own include Aurora Cannabis (ACB), Air Canada (AC), Arbutus Biopharma (ABUS), AB Science (ABSCF), AB International Group (ABQQ), AB Dynamics (ABDP) and Advantage Energy (AAV). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:EPI CIKN/A Webessapharmaceuticals.com Phone+1-778-3310962FaxN/AEmployees25Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.04 Current Ratio37.29 Quick Ratio36.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$2.21 per share Price / Cash Flow3.72 Book ValueC$2.21 per share Price / Book3.72Miscellaneous Outstanding Shares29,009,000Free FloatN/AMarket CapC$237.87 million OptionableNot Optionable BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (CVE:EPI) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredBillionaire Trader Warns: Get Out of StocksRay Dalio - who has made more money for clients than any hedge fund manager in history - is warning of a histo...TradeSmith | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredGold to $4,900—Here’s the Real PlayGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ESSA Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ESSA Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
